A Phase 2 interventional study of BR55 in Pancreatic Ductal Adenocarcinoma, sponsored by Bracco Diagnostics, Inc. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-23.
Sponsored by Bracco Diagnostics, Inc (part of Bracco) · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.
Approximately twenty-four (24) subjects with suspected PDAC and scheduled to undergo surgical resection within 30 days (but not before 24 hours) after the transabdominal BR55 CEUS examination will be enrolled into 3 dose groups, 0.03, 0.05, and 0.08 mL/kg, with a maximum of 8 patients in each dose group.
Bracco Diagnostics, Inc is the lead sponsor of 49 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Enroll a subject in this study if the subject meets the following inclusion criteria:
Exclusion Criteria:
Exclude a subject from this study if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed:
Is a pregnant or lactating female. Exclude the possibility of pregnancy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.
Drug: BR55
A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.
Drug: BR55
A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.
Drug: BR55
A novel targeted ultrasound contrast agent
1. Visual Assessment of Enhancement
BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement, weak enhancement, strong enhancement).
Time frame: Up to 24 hours post-dose on Day 1
2. Adverse Events
Number of participants who received the contrast agent and experienced an adverse event.
Time frame: From the time of signing Informed Consent through 24 hours post-dose, up to a maximum of 11 days
| Milestone | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group |
|---|---|---|---|
| Started | 4 | 0 | 0 |
| Completed | 4 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement, weak enhancement, strong enhancement).
| Participants | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group |
|---|---|---|---|
| No enhancement | 0 | — | — |
| Weak enhancement | 3 | — | — |
| Strong enhancement | 1 | — | — |
Number of participants who received the contrast agent and experienced an adverse event.
| Participants | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group |
|---|---|---|---|
| 2. Adverse Events | 2 | 0 | 0 |
Collected over Safety monitoring began at the time of signing Informed Consent and continued for 24 hours after BR55 administration, up to a maximum of 11 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.03mL/kg Dose Group | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| 0.05mL/kg Dose Group | — | — | — |
| 0.08mL/kg Dose Group | — | — | — |
| Event | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 1/4 | — | — |
| VomitingGastrointestinal disorders | 1/4 | — | — |
As of July 31, 2021, enrollment was terminated for Study BR55-110 due to expiration of available BR55. Therefore, only 4 participants were enrolled in the first cohort of this study (0.03 mL/kg). No participant was enrolled in the 0.05 mL/kg or 0.08 mL/kg groups.
| Age, Categorical(Participants) | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group | Total |
|---|---|---|---|---|
| <=18 years | 0 | — | — | 0 |
| Between 18 and 65 years | 3 | — | — | 3 |
| >=65 years | 1 | — | — | 1 |
| Age, Continuous(years) | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group | Total |
|---|---|---|---|---|
| Mean | 65.5 (60 to 78) | — | — | 65.5 (60 to 78) |
| Sex: Female, Male(Participants) | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group | Total |
|---|---|---|---|---|
| Female | 0 | — | — | 0 |
| Male | 4 | — | — | 4 |
| Race (NIH/OMB)(Participants) | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | — | — | 1 |
| Asian | 1 | — | — | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | — | — | 0 |
| Black or African American | 0 | — | — | 0 |
| White | 2 | — | — | 2 |
| More than one race | 0 | — | — | 0 |
| Unknown or Not Reported | 0 | — | — | 0 |
| Region of Enrollment(participants) | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group | Total |
|---|---|---|---|---|
| United States | 4 | — | — | 4 |
| Total Volume (mL) Injected(mL) | 0.03mL/kg Dose Group | 0.05mL/kg Dose Group | 0.08mL/kg Dose Group | Total |
|---|---|---|---|---|
| Mean | 2.00 (1.60 to 2.37) | — | — | 2.00 (1.60 to 2.37) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Nov 2020, 27 months.
Results were first posted in Aug 2024, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BR55